Differential effects of immunosuppressants and antibiotics on human monoclonal antibody production in SCID mouse ascites by five heterohybridomas

Hybridoma

Volumn 17, Issue 1, 1998, Pages 41-46

  Yoshinari, Kaoru ^a   Arai, Kenji ^a  

^a ASAHI CHEMICAL INDUSTRY CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPTERIN; ANTIBIOTIC AGENT; GANGLIOTETRAOSYLCERAMIDE; HYPOXANTHINE; IMMUNOSUPPRESSIVE AGENT; KANAMYCIN; MONOCLONAL ANTIBODY; PENICILLIN G; PRISTANE; STREPTOMYCIN; THYMIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; ASCITES TUMOR; CELL FUSION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; HYBRIDOMA; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG CANCER; LYMPH NODE CELL; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE;

ANIMALIA; MURINAE;

EID: 0031934069     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.1998.17.41     Document Type: Article

References (25)

1. Truitt KE, Larrick JW, Raubitschek AA, Buck DW, and Jacobson SW: Production of human monoclonal antibody in mouse ascites. Hybridoma 1984;3:195-199.
2. Kozbor D, Abramow-Newerly W, Tripputi P, Cole SPC, Weibel J, Roder JC, and Croce CM: Specific immunoglobulin production and enhanced tumorigenicity following ascites growth of human hybridomas. J Immunol Meth 1985;81:31-42.
3. Jahn S, Grunow R, Kiessig ST, Bogacheva GT, Arsenjeva EL, Hlinak A, Rocklin OV, and Von Baehr R: Cell biology of human IgM-producing hybridomas derived from a fusion of human spleen lymphocytes with mouse myeloma cell. Hybridoma 1987;6:679-687.
4. Suzuki H, Okubo Y, Moriyama M, Sasaki M, and Hozumi T: Human monoclonal antibodies to Pseudomonas aeruginosa produced by EBV-transformed cells. Microbiol Immunol 1987;31:959-966.
5. Matsumoto M, Mochizuki K, and Kobayashi Y: Productive ascites growth of heterohybridomas between Epstein-Barr virus-transformed human B cells and murine P3X63Ag8.653 myeloma cells. Microbiol Immunol 1989;33:883-886.
6. Pistillo MP, Sguerso V, and Ferrara GB: High yields of anti-HLA human monoclonal antibodies can be provided by SCID mice. Hum Immunol 1992;35:256-259.
7. Bosma GC, Custer RP, and Bosma MJ: A severe combined immunodeficiency mutation in the mouse. Nature 1983;301:527-530.
8. Dorshkind KS, Pollack SB, Bosma MJ, and Phillips RA: Natural killer (NK) cells are present in mice with severe combined immunodeficiency (SCID). J Immunol 1985;134:3798-3801.
9. Welsh RM, Brubaker JO, Vargas-Cortes M, and O'Donnell CL: Natural killer (NK) cell response to virus infections in mice with severe immunodeficiency. The stimulation of NK cells and the NK cell-dependent control of virus infections occur independently of T and B cell function. J Immunol 1991;173:1053-1063.
10. Yoshinari K, Kimura H, Arai K, Sugawara I, Noda K, Kihara M, Misaki H, and Yamaguchi Y: Generation of human monoclonal antibodies recognizing membranous antigens of the lung adenocarcinoma cell line A549 using an AMeX immunohistostaining method. Br J Cancer 1996;74:359-367.
11. Habu S, Fukui H, Shimamura K, Kasai M, Nagai Y, Okumura K, and Tamaoki N: In vivo effects of anti-asialo GM1 1. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol 1981;127:34-38.
12. Murphy W, Kumar V, and Bennett M: Rejection of bone marrow allografts by mice with severe combined immune deficiency (SCID). J Exp Med 1987;165:1212-1217.
13. Freund YR, and Blair PB: Depression of natural killer activity and mitogen responsiveness in mice treated with pristane. J Immunol 1982;129:2826-2830.
14. Potter M, and Wax JS: Peritoneal plasmacytomagenesis in mice: Comparison of different pristane dose regimens. J Natl Cancer Inst 1983;71:391-395.
15. Hoogenraad N, Helman T, and Hoogenraad J: The effect of pre-injection of mice with pristane on ascites tumour formation and monoclonal antibody production. J Immunol Meth 1983;61:317-320.
16. Brodeur BR, Tsang P, and Larose Y: Parameters affecting ascite tumour formation in mice and monoclonal antibody production. J Immunol Meth 1984;71:265-272.
17. Abrams PG, Ochs JJ, Giardina SL, Morgan AC, Wilburn SB, Wilt AR, Oldham RK, and Foon KA: Production of large quantities of human immunoglobulin in the ascites of athymic mice: Implications for the development of anti-human idiotype monoclonal antibodies. J Immunol 1984;132:1611-1613.
18. Ware CF, Donato NJ, and Dorshkind K: Human, rat or mouse hybridomas secrete high levels of monoclonal antibodies following transplantation into mice with severe combined immunodeficiency disease (SCID). J Immunol Meth 1985;85:353-361.
19. Hoogenraad NL, and Wraight CJ: The effect of pristane on ascites tumor formation and monoclonal antibody production. Meth Enzymol 1986;121:375-381.
20. Youmans AS, and Youmans GP: Effect of metabolic inhibitors on the formation of antibody to sheep erythrocytes, on the development of delayed hypersensitivity, and on immune response to infection with mycobacterium tuberculosis in mice. Infect Immun 1978;19:212-216.
21. Voiculescu C, Stanciu L, Voiculescu M, Rogoz S, Dumitriu I, and Nedelcu C: Experimental study of antibiotic-induced immunosuppression in mice-II. Comp Immun Microbiol Infect Dis 1983;6: 301-312.
22. Villa ML, Rapocciolo G, Piazza P, and Clerici E: The interference of antibiotics with antigen-specific antibody responses in man. Int J Immunopharmac 1986;8:805-809.
23. Siegenthaler W, Bonetti A, and Luthy R: Aminoglycoside antibiotics in infectious diseases. Am J Med 1986;80:2-14.
24. Hazama S, Kikuchi C, and Kanno M: Influence of aminoglycoside antibiotics, streptomycin and kanamycin on histamine secretion in mast cells. J Toxicol Sci 1992;17:1-11.
25. Harlow E, and Lane D: Monoclonal antibodies. In: Antibodies: A laboratory manual; Cold Spring Harbor Laboratory, New York, 1989, pp. 139-243.